Canada markets close in 2 hours 21 minutes

PFE Jun 2023 37.500 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.6500-0.0200 (-2.99%)
As of 12:55PM EST. Market open.
Full screen
Previous Close0.6700
Open0.6600
Bid0.6300
Ask0.6800
Strike37.50
Expire Date2023-06-16
Day's Range0.6500 - 0.6600
Contract RangeN/A
Volume2
Open Interest3.01k
  • Business Wire

    Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

    NEW YORK, November 28, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals Business; Kevin Sullivan, Global Specialty Care & U.S. President; and Navin Katyal, U.S. Commercial and Global Business Lead for mRNA Portfolio, at the Evercore ISI HealthCONx Conference on Thursday, December 1, 2022 at 4:20 p.m. EST.

  • Simply Wall St.

    Pfizer Inc. (NYSE:PFE) On An Uptrend: Could Fundamentals Be Driving The Stock?

    Most readers would already know that Pfizer's (NYSE:PFE) stock increased by 6.4% over the past three months. We wonder...

  • Reuters

    Researchers test mRNA technology for universal flu vaccine

    An experimental vaccine provided broad protection against all 20 known influenza A and B virus subtypes in initial tests in mice and ferrets, potentially opening a pathway to a universal flu shot that might help prevent future pandemics, according to a U.S. study published on Thursday. The two-dose vaccine employs the same messenger RNA (mRNA)technology used in the COVID-19 shots developed by Pfizer with BioNTech, and by Moderna. It delivers tiny lipid particles containing mRNA instructions for cells to create replicas of so-called hemagglutinin proteins that appear on influenza virus surfaces.